RT Journal Article
SR Electronic
T1 Comparison of Changes in Tumor Metabolic Activity and Tumor Size During Chemotherapy of Adenocarcinomas of the Esophagogastric Junction
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 2029
OP 2034
VO 46
IS 12
A1 Hinrich A. Wieder
A1 Ambros J. Beer
A1 Florian Lordick
A1 Katja Ott
A1 Michael Fischer
A1 Ernst J. Rummeny
A1 Sibylle Ziegler
A1 Jörg R. Siewer
A1 Markus Schwaiger
A1 Wolfgang A. Weber
YR 2005
UL http://jnm.snmjournals.org/content/46/12/2029.abstract
AB We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size. Methods: Twenty patients with adenocarcinoma of the esophagogastric junction (AEG) were studied by 18F-FDG PET and CT scans before neoadjuvant chemotherapy, 14 d after the initiation of therapy, and 4 wk after the completion of therapy. Results: The relative change in 18F-FDG uptake was more than 2 times larger than the decrease in tumor size at all time points (P < 0.01). At 14 d after the initiation of chemotherapy, there was no correlation between the reduction in 18F-FDG uptake and tumor wall thickness. The change in 18F-FDG uptake after 14 d of therapy was significantly correlated with the reduction in tumor size after the completion of therapy. Conclusion: In AEG, changes in tumor metabolism are a more sensitive parameter for assessing the effects of chemotherapy than are changes in tumor size. Early changes in metabolic activity predict the subsequent reduction in tumor size.